Stroke RSS

Filtered By:
Condition: Arrhythmia
Procedure: Transplants

This page shows you your search results in order of date.

Order by Relevance | Date

Total 69 results found since Jan 2013.

Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe
Eur Respir Rev. 2022 Nov 2;31(166):220098. doi: 10.1183/16000617.0098-2022. Print 2022 Dec 31.ABSTRACTBACKGROUND: As mortality from coronavirus disease 2019 (COVID-19) is strongly age-dependent, we aimed to identify population subgroups at an elevated risk for adverse outcomes from COVID-19 using age-/gender-adjusted data from European cohort studies with the aim to identify populations that could potentially benefit from booster vaccinations.METHODS: We performed a systematic literature review and meta-analysis to investigate the role of underlying medical conditions as prognostic factors for adverse outcomes due to sever...
Source: Respiratory Care - November 2, 2022 Category: Respiratory Medicine Authors: Constantine I Vardavas Alexander G Mathioudakis Katerina Nikitara Kimon Stamatelopoulos Georgios Georgiopoulos Revati Phalkey Jo Leonardi-Bee Esteve Fernandez Dolors Carnicer-Pont J ørgen Vestbo Jan C Semenza Charlotte Deogan Jonathan E Suk Piotr Kramarz Source Type: research

Heart transplantation strategies in arrhythmogenic right ventricular cardiomyopathy: a tertiary ARVC centre experience
ConclusionsHeart transplantation is a curative treatment for ARVC, but due to frequent ventricular arrhythmias and RV predominant pathology, patients require unique considerations in regard to timing of evaluation, haemodynamic support options, and wait listing qualification.
Source: ESC Heart Failure - December 25, 2021 Category: Cardiology Authors: Paul J. Scheel, Katherine Giuliano, Crystal Tichnell, Cynthia James, Brittney Murray, Harikrishna Tandri, Debra Carter, Tracey Fehr, Priya Umapathi, Joban Vaishnav, Sabra C. Lewsey, Steven Hsu, Hugh Calkins, Kavita Sharma, Chun Woo Choi, Ni Tags: Original Article Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Troubleshooting Left Ventricular Assist Devices: Modern Technology and Its Limitations
AbstractPurpose of reviewAs the incidence of heart failure continues to rise, modern generation left ventricular assist devices (LVADs) have become the primary therapeutic modality used as both bridge to transplant (BTT) and destination therapy (DT) in patients with acute and chronic heart failure. This review aims to highlight the progression of LVAD technology, outline LVAD complications and manifestations, and provide evidence-based therapeutic methods to troubleshoot such adverse events.Recent findingsDespite modern innovation, LVAD adverse events continue to hinder the progress of HF paradigms and are associated with ...
Source: Current Treatment Options in Cardiovascular Medicine - August 2, 2021 Category: Cardiology Source Type: research

Early postoperative effects of kidney transplantation on the cardiovascular system in our clinical practice
CONCLUSION: After transplantation, the left atrial and the end-systolic diameter of the left ventricle regrediated, decreasing the frequency of arrhythmic episodes. The number of the middle grade mitral valve regurgitation decreased and the calcification among diabetic population increased significantly. Orv Hetil. 2021; 162(26): 1052-1062.PMID:34175832 | DOI:10.1556/650.2021.32269
Source: Orvosi Hetilap - June 27, 2021 Category: General Medicine Authors: Andrea Darag ó Gerda Schwegler Eszter Szab ó Dorina Bark ó R éka P Szabó Attila Csaba Nagy Gerg ő József Szőllősi Bal ázs Nemes Source Type: research

A vesetranszplant áció korai posztoperatív hatásai a szív- és érrendszeri betegségekre klinikai gyakorlatunkban
CONCLUSION: After transplantation, the left atrial and the end-systolic diameter of the left ventricle regrediated, decreasing the frequency of arrhythmic episodes. The number of the middle grade mitral valve regurgitation decreased and the calcification among diabetic population increased significantly. Orv Hetil. 2021; 162(26): 1052-1062.PMID:34175832 | DOI:10.1556/650.2021.32269
Source: Orvosi Hetilap - June 27, 2021 Category: General Medicine Authors: Andrea Darag ó Gerda Schwegler Eszter Szab ó Dorina Bark ó R éka P Szabó Attila Csaba Nagy Gerg ő József Szőllősi Bal ázs Nemes Source Type: research

Hypertrophic cardiomyopathy considerations for the managed care pharmacist
Am J Manag Care. 2021 Apr;27(6 Suppl):S118-S125. doi: 10.37765/ajmc.2021.88629.ABSTRACTHypertrophic cardiomyopathy (HCM) is often seen in patients as an autosomal dominant genetic heart disease with a variable clinical course. It is characterized by left ventricular hypertrophy, and with some patients, there is no evidence of a genetic etiology or presence of HCM in family members. Young age at diagnosis and the presence of a pathogenic or likely pathogenic sarcomere variant predict greater lifelong risk for stroke, heart failure, ventricular arrhythmia, atrial fibrillation, or mortality. Most individuals affected with HCM...
Source: The American Journal of Managed Care - April 16, 2021 Category: Health Management Authors: Patty Taddei-Allen Source Type: research

Pages: 1 2 3 4 5